한국형 양극성 장애 약물치료 알고리듬 2022: 총론open accessKorean Medication Algorithm Project for Bipolar Disorder 2022: Overview
- Authors
- 김원; 박원명; 우영섭; 정종현; 서정석; 추일한; 양찬모; 이정구; 심세훈; 정명훈; 전덕인; 박성용; 손인기; 김문두; 윤보현
- Issue Date
- May-2022
- Publisher
- 대한신경정신의학회
- Keywords
- Bipolar disorder; KMAP-BP 2022; Pharmacotherapy; Algorithm
- Citation
- 신경정신의학, v.61, no.2, pp 98 - 109
- Pages
- 12
- Journal Title
- 신경정신의학
- Volume
- 61
- Number
- 2
- Start Page
- 98
- End Page
- 109
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61346
- DOI
- 10.4306/jknpa.2022.61.2.98
- ISSN
- 1015-4817
2289-0963
- Abstract
- Objectives The pharmacotherapy of bipolar disorder is complex. A treatment guideline or algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was revised through expert consensus on pharmacotherapy for bipolar disorder.
Methods We revised the KMAP-BP 2018 questionnaire and conducted a survey of expert clinicians.
Out of ninety-three members of the review committee, eighty-seven completed the survey.
We analyzed the answers, discussed the data, and held a clinician hearing. Here, we report the results from KMAP-BP 2022.
Results The preferred first-step strategies for acute euphoric mania are a combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy.
For psychotic mania, an MS and AAP combination, and AAP monotherapy are preferred.
For hypomania, MS monotherapy and AAP monotherapy are preferred. The first-step strategies for mild to moderate bipolar depression are MS monotherapy, lamotrigine (LMT) monotherapy, AAP monotherapy, an MS+AAP combination, and an AAP+LMT combination. For non-psychotic severe depression, the MS+AAP combination, the AAP+LMT combination, and the MS+LMT combination are preferred. For psychotic severe depression, MS+AAP and AAP+LMT are preferred.
Conclusion We obtained expert consensus and developed KMAP-BP 2022. Compared with KMAP-BP 2018, we can figure out clinicians’ preferences and decisions in real clinical situations more clearly. The preference for AAP increased, and that of MS and an antidepressant decreased.
We hope KMAP-BP 2022 is helpful for clinicians who treat patients with bipolar disorder.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.